MX376437B - Uso de hígado descelularizado por perfusión para recelularización de células de islote. - Google Patents

Uso de hígado descelularizado por perfusión para recelularización de células de islote.

Info

Publication number
MX376437B
MX376437B MX2015013154A MX2015013154A MX376437B MX 376437 B MX376437 B MX 376437B MX 2015013154 A MX2015013154 A MX 2015013154A MX 2015013154 A MX2015013154 A MX 2015013154A MX 376437 B MX376437 B MX 376437B
Authority
MX
Mexico
Prior art keywords
liver
perfusion
decelularized
recellularization
islet cells
Prior art date
Application number
MX2015013154A
Other languages
English (en)
Other versions
MX2015013154A (es
Inventor
Jeffrey Ross
Original Assignee
Miromatrix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miromatrix Medical Inc filed Critical Miromatrix Medical Inc
Publication of MX2015013154A publication Critical patent/MX2015013154A/es
Publication of MX376437B publication Critical patent/MX376437B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención se refiere a un método para preparar células de islote basadas en perfusión que contienen matriz extracelular de hígado, una matriz extracelular recelularizada de células de islote y métodos de uso de la matriz recelularizada.
MX2015013154A 2013-03-15 2014-03-13 Uso de hígado descelularizado por perfusión para recelularización de células de islote. MX376437B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789927P 2013-03-15 2013-03-15
PCT/US2014/026363 WO2014151739A1 (en) 2013-03-15 2014-03-13 Use of perfusion decellularized liver for islet cell recellularization

Publications (2)

Publication Number Publication Date
MX2015013154A MX2015013154A (es) 2016-07-13
MX376437B true MX376437B (es) 2025-03-04

Family

ID=50639947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013154A MX376437B (es) 2013-03-15 2014-03-13 Uso de hígado descelularizado por perfusión para recelularización de células de islote.

Country Status (13)

Country Link
US (3) US10213525B2 (es)
EP (1) EP2970891B1 (es)
JP (3) JP2016513465A (es)
KR (4) KR20240104179A (es)
CN (1) CN105164250A (es)
AU (1) AU2014236952B2 (es)
BR (1) BR112015023642A2 (es)
CA (1) CA2907161A1 (es)
ES (1) ES2831756T3 (es)
HK (1) HK1218929A1 (es)
MX (1) MX376437B (es)
SG (2) SG10201906304TA (es)
WO (1) WO2014151739A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006282783B2 (en) 2005-08-26 2013-06-06 Miromatrix Medical Inc. Decellularization and recellularization of organs and tissues
US20140342984A1 (en) * 2007-10-19 2014-11-20 Robert G. Matheny Compositions for Regenerating Defective or Absent Myocardium
ES2562707T3 (es) 2010-09-01 2016-03-07 Regents Of The University Of Minnesota Métodos de recelularización de un tejido u órgano para una mejor capacidad de trasplante
MX376437B (es) 2013-03-15 2025-03-04 Miromatrix Medical Inc Uso de hígado descelularizado por perfusión para recelularización de células de islote.
KR101636954B1 (ko) 2013-11-04 2016-07-08 대한민국 재세포화된 바이오 스캐폴드 및 이의 제조방법
SG11201707924VA (en) * 2015-03-26 2017-10-30 Miromatrix Medical Inc Gas filled decellularized extracellular matrix
ES2749160T3 (es) 2015-09-11 2020-03-19 Massachusetts Gen Hospital Regeneración de un lecho vascular pulmonar funcional
EP3509651B1 (en) 2016-09-06 2022-12-28 Miromatrix Medical Inc. Use of resected liver serum for whole liver engineering
JP7265988B2 (ja) * 2017-02-03 2023-04-27 コーネル ユニヴァーシティー 安定な３次元血管およびそれを形成するための方法
CN106693076A (zh) * 2017-03-13 2017-05-24 浙江保尔曼生物科技有限公司 去细胞皮瓣及其制备方法和应用
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
GB201807788D0 (en) * 2018-05-14 2018-06-27 Ucl Business Plc Method
WO2019241499A1 (en) 2018-06-13 2019-12-19 Miromatrix Medical Inc. Fistula filler and deployment system
CA3103273A1 (en) 2018-06-21 2019-12-26 Yale University Bioartificial vascular pancreas
AU2020241583A1 (en) * 2019-03-21 2021-10-14 Miromatrix Medical Inc. Improved decellularization of isolated organs
US12383657B1 (en) 2021-06-09 2025-08-12 Reprise Biomedical, Inc. Biologic matrix for a wound site and related methods
US11998662B1 (en) 2021-06-09 2024-06-04 Reprise Biomedical, Inc. Biologic matrix for a wound site and related methods
DE102021211875B3 (de) * 2021-10-21 2023-01-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, Körperschaft des öffentlichen Rechts Bioreaktor und Verfahren zum Betrieb eines solchen
CN120322256A (zh) * 2022-08-24 2025-07-15 费尔克拉夫特公司 用于人造真皮层的支架材料
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用
EP4619054A1 (en) 2022-11-18 2025-09-24 Vantive Health GmbH Extracorporeal blood treatment for organ support
KR102714328B1 (ko) 2024-07-07 2024-10-11 한상관 녹조 발생 방지용 자연친화적인 친환경 가동보를 이용하여 대형 빗물 저류조 기능과 산불진화용 빗물저류조 기능을 발휘시킴과 동시에 홍수피해 방지용 빗물저류조 기능을 발휘함과 동시에 하천, 강,호수, 댐, 저수지,하구언에 저수되어 있는 오염된 하천수를 자연정화 시키면서 3중 양수 공법으로 전기를 생산하는 자연친화적인 친환경 공법

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545221A (en) 1967-05-22 1970-12-08 Swenko Research & Dev Inc Apparatus for maintaining organs in vitro in a completely viable state
US3639084A (en) 1970-04-06 1972-02-01 Baxter Laboratories Inc Mechanism for control pulsatile fluid flow
DE2453363B2 (de) 1974-11-11 1976-08-26 Solco Basel AG, Birsfelden (Schweiz) Verfahren zur herstellung heterologer arterientransplantate
JPS5516016A (en) 1978-07-18 1980-02-04 Dai Ichi Kogyo Seiyaku Co Ltd Improved salt-resistant water-absorbing material
US4801299A (en) 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
WO1996008213A1 (en) 1994-09-12 1996-03-21 Advanced Tissue Sciences, Inc. Three-dimensional human cell cultures on cardiac valve frameworks and their uses
ES2231980T3 (es) 1997-04-11 2005-05-16 Cryolife, Inc. Descelurizacion de un tejido.
JPH1176400A (ja) 1997-09-09 1999-03-23 Masahito Nagaki 人工臓器
JP4222658B2 (ja) 1998-06-23 2009-02-12 テルモ株式会社 細胞支持基材、培養装置および液体処理装置
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
US6448076B2 (en) 1998-09-15 2002-09-10 The Regents Of The University Of Michigan Method for chemically acellularizing a biological tissue sample
US6432712B1 (en) 1999-11-22 2002-08-13 Bioscience Consultants, Llc Transplantable recellularized and reendothelialized vascular tissue graft
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US20050249816A1 (en) 1999-12-29 2005-11-10 Wake Forest University Health Services Tissue engineered liver constructs
US6689161B2 (en) 2000-04-28 2004-02-10 Baylor College Of Medicine Decellularized vascular prostheses resistant to thrombus occlusion and immunologic rejection
DE10021627B4 (de) 2000-05-04 2009-11-19 Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich Verfahren zur Herstellung eines vaskularisierten bioartifiziellen Gewebes und zugehöriger Versuchsreaktor
WO2002014480A2 (en) 2000-08-16 2002-02-21 Duke University Decellularized tissue engineered constructs and tissues
US6749064B1 (en) 2000-08-25 2004-06-15 Sanita L. Alrey Bag with article display aperture and support surface
AU2001292917A1 (en) 2000-09-20 2002-04-02 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
IL139708A0 (en) 2000-11-15 2002-02-10 Amiel Gilad Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
US7311904B2 (en) 2001-02-14 2007-12-25 Anthrogenesis Corporation Tissue matrices comprising placental stem cells, and methods of making the same
DE10064948C1 (de) 2000-12-20 2002-07-11 Auto Tissue Gmbh Verfahren zur Dezellularisierung von Fremdmaterial zur Herstellung von Bioprothesen und Vorrichtung zur Durchführung des Verfahrens
CA2445110A1 (en) 2001-05-01 2002-11-07 Universite Du Quebec A Montreal Tridimensional biocompatible support structure for bioartificial organs and uses thereof
GB2375771A (en) 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
EP1317934A1 (de) 2001-11-08 2003-06-11 Artiss GmbH Verfahren zur Herstellung einer azellularisierten Gewebematrix und damit erhältliche Gewebematrix
WO2003043674A1 (en) 2001-11-16 2003-05-30 Children's Medical Center Corporation ¨ Augmentation of organ function
DE60239217D1 (de) 2001-11-16 2011-03-31 Childrens Medical Center Erzeugung gewebetechnologisch hergestellter weiblicher fortpflanzungsorgane
US20030180268A1 (en) 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
JP4149897B2 (ja) 2002-11-07 2008-09-17 学校法人 聖マリアンナ医科大学 気管移植片の調製方法および気管移植片
US20040187877A1 (en) 2002-12-04 2004-09-30 Badylak Stephen F. Method for repair of liver tissue
AU2003296672A1 (en) 2002-12-13 2004-07-09 Cilag Ag Controlled release preparations comprising tramadol and topiramate
US20040175366A1 (en) * 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
US20040176855A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Decellularized liver for repair of tissue and treatment of organ deficiency
JP2006223101A (ja) 2003-05-15 2006-08-31 Univ Waseda 生体組織の保持装置及びこれを用いた生体組織処理装置
WO2005118014A2 (en) 2004-06-01 2005-12-15 Medtronic, Inc. Decellurisation processes for making bioprotheses
JP3773943B2 (ja) 2004-09-24 2006-05-10 国立大学法人 東京大学 把持状態判定システム及び方法
DE102005023599A1 (de) 2005-05-18 2006-11-23 Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich Bioartifizielles Herzgewebetransplantat und Verfahren zu seiner Herstellung
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
WO2007002228A1 (en) 2005-06-23 2007-01-04 Massachusetts Institute Of Technology Methods for ex vivo propagation of adult hepatic stem cells
US20100093066A1 (en) 2005-08-26 2010-04-15 Regents Of The University Of Minnesota Decellularization and recellularization apparatuses and systems containing the same
AU2006282783B2 (en) 2005-08-26 2013-06-06 Miromatrix Medical Inc. Decellularization and recellularization of organs and tissues
AU2013224686B2 (en) 2005-08-26 2015-06-11 Miromatrix Medical Inc. Decellularization and recellularization of organs and tissues
JP4599315B2 (ja) 2006-02-23 2010-12-15 クラレメディカル株式会社 バイオ人工臓器
CN101066477B (zh) 2007-05-17 2010-10-06 中国人民解放军第三军医大学 能在体捕获内皮祖细胞的生物人工血管
AU2008334036B2 (en) 2007-11-30 2014-05-29 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
IL196820A0 (en) * 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
RU2011143730A (ru) * 2009-03-31 2013-05-10 Риджентс Оф Дзе Юниверсити Оф Миннесота Децеллюляризации и рецеллюляризация органов и тканей
US20130323708A1 (en) * 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same
WO2011059808A2 (en) * 2009-10-29 2011-05-19 The General Hospital Corporation Methods for generating pancreatic tissue
EP2588592B1 (en) 2010-06-30 2017-09-06 Miromatrix Medical Inc. Use of perfusion decellularized organs for matched recellularization
ES2879246T3 (es) * 2010-07-02 2021-11-22 Univ North Carolina Chapel Hill Andamios de biomatriz
ES2562707T3 (es) * 2010-09-01 2016-03-07 Regents Of The University Of Minnesota Métodos de recelularización de un tejido u órgano para una mejor capacidad de trasplante
EP2667878B1 (en) 2011-01-25 2016-03-30 Université Catholique de Louvain Compositions and methods for cell transplantation
WO2013016544A2 (en) 2011-07-27 2013-01-31 University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US9290738B2 (en) 2012-06-13 2016-03-22 Miromatrix Medical Inc. Methods of decellularizing bone
MX376437B (es) 2013-03-15 2025-03-04 Miromatrix Medical Inc Uso de hígado descelularizado por perfusión para recelularización de células de islote.
SG11201507673WA (en) 2013-03-15 2015-10-29 Miromatrix Medical Inc Use of microparticles and endothelial cells with decellularized organs and tissues
JP6340772B2 (ja) 2013-11-08 2018-06-13 東ソー株式会社 パラメータ変更履歴を管理可能な分析装置
SG11201707924VA (en) 2015-03-26 2017-10-30 Miromatrix Medical Inc Gas filled decellularized extracellular matrix
EP3509651B1 (en) 2016-09-06 2022-12-28 Miromatrix Medical Inc. Use of resected liver serum for whole liver engineering

Also Published As

Publication number Publication date
US20230293770A1 (en) 2023-09-21
BR112015023642A2 (pt) 2017-07-18
SG10201906304TA (en) 2019-08-27
WO2014151739A1 (en) 2014-09-25
KR20210090299A (ko) 2021-07-19
KR20230061578A (ko) 2023-05-08
CA2907161A1 (en) 2014-09-25
KR20160026839A (ko) 2016-03-09
US11452797B2 (en) 2022-09-27
HK1218929A1 (zh) 2017-03-17
AU2014236952B2 (en) 2019-10-17
CN105164250A (zh) 2015-12-16
ES2831756T3 (es) 2021-06-09
SG11201507620VA (en) 2015-10-29
JP2019141661A (ja) 2019-08-29
US20160030638A1 (en) 2016-02-04
JP2020099344A (ja) 2020-07-02
AU2014236952A1 (en) 2015-11-05
EP2970891A1 (en) 2016-01-20
JP2016513465A (ja) 2016-05-16
KR102577616B1 (ko) 2023-09-11
JP6781352B2 (ja) 2020-11-04
KR102278652B1 (ko) 2021-07-19
MX2015013154A (es) 2016-07-13
KR20240104179A (ko) 2024-07-04
US10213525B2 (en) 2019-02-26
EP2970891B1 (en) 2020-10-21
US20190381212A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX376437B (es) Uso de hígado descelularizado por perfusión para recelularización de células de islote.
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
MX373383B (es) Metodo para preparar rebaudiosido m mediante el uso de un metodo con enzima.
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CR20150519A (es) Compuestos de 1, 3-oxazin-2-amina fusionados con cilopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
UY34765A (es) Compuestos novedosos.
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
DK3116902T3 (da) Fremgangsmåde til generering af T-celler kompatible for allogen transplantation
BR112013028422A2 (pt) ativadores de piruvato cinase para uso em terapia
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
CL2015003147A1 (es) Compuestos de biheteroarilo y usos de los mismos
UY33957A (es) Moduladores de los receptores de hormonas nucleares
MX2020009670A (es) Metodos de cultivo por perfusion y usos de los mismos.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
BR112015009488B8 (pt) Método de preparação de nanopartículas de óxido de ferro (iii), nanopartículas de óxido de ferro (iii), material para anodo, anodo e dispositivo eletroquímico
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
BR112014008631A2 (pt) método para preparação de células solares sensibilizadas por corantes e células solares assim produzidas

Legal Events

Date Code Title Description
FG Grant or registration